Swift Biosciences has launched a COVID-19 kit to help research and surveillance teams with low viral titers in clinical specimens.
The Swift Normalase Amplicon Panel (SNAP) SARS-CoV-2 kit uses a single tube reaction to target the full viral genome. The two-round polymerase chain reaction (PCR) kit converts and enriches complementary DNA (cDNA) into multiplexed, next-generation sequencing (NGS) libraries, according to the company.
Pathologists at the New York University Grossman School of Medicine have used the SNAP SARS-CoV-2 kit to identify mutations in low viral load samples, according to Swift. The kit works in a two-hour timeframe and can support high-throughput processing, the company said.